Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

DocuSign drops 6% as UBS downgrades to sell on valuation, sees 20% downside risk

Published 02/21/2023, 09:19 AM
Updated 02/21/2023, 09:25 AM
© Reuters.  DocuSign (DOCU) drops 6% as UBS downgrades to Sell on valuation, sees 20% downside risk

By Senad Karaahmetovic

Shares of DocuSign (NASDAQ:DOCU) are trading over 6% lower in pre-open Tuesday after UBS analysts downgraded shares to Sell from Neutral.

The analysts highlighted a +54% move in DOCU shares since the December lows, which makes the valuation too expensive.

“21.2x CY24/FY25E FCF does not look compelling relative to Zoom and other low-growth software peers,” they said in a downgrade note.

DOCU shares reacted positively to last week’s announcement of a new 10% workforce reduction, which came after the company had slashed 9% of jobs in September.

“We were on the sidelines and Neutral-rated throughout 2H22 and into 2023, hesitant to move to an even more cautious rating based on a view that there was maximum negativity already embedded in the stock and that at <20x CY23/FY24E FCF, DocuSign’s multiple wasn’t demanding. Our view has changed given the +54% move in the stock off the December lows, the current CY23/FY24E FCF multiple of 26.0x and fundamentals that if anything have weakened,” they added.

The price target of $52 per share, which suggests a downside risk of about 20%, also takes into account lowered estimates for FY24.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.